لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Tahri S; Dana-Farber Cancer Institute, United States., Piccinelli S; Dana-Farber Cancer Institute, Boston, Massachusetts, Netherlands., Su NK; Harvard Medical School, United States., Lampe LM; Christian-Albrechts University, Germany., Dong H; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Vergara Cadavid J; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Boiarsky R; CSAIL, United States., Papazian N; Erasmus MC, Rotterdam, Netherlands., Lightbody ED; Harvard Medical School, United States., Cao A; Harvard Medical School, United States., Alberge JB; Harvard Medical School, United States., Ferrari de Andrade L; Icahn School of Medicine at Mount Sinai, New York, New York, United States., Rahmat M; Harvard Medical School, United States., Shen Y; Cancer Science Institute of Singapore, Singapore., Blanco Fernández L; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Zabaleta A; Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Guenther A; Christian-Albrechts University, Kiel, Germany., Getz G; Broad Institute, Mass General Hospital, Cambridge, Massachusetts, United States., Sonneveld P; Erasmus MC Cancer Institute Rotterdam, Rotterdam, Netherlands., Cupedo T; Erasmus University Medical Center, Rotterdam, Netherlands., Wucherpfennig KW; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Ghobrial IM; Harvard Medical School, United States., Romee R; Harvard Medical School, United States.

المصدر: Blood advances [Blood Adv] 2024 Aug 06. Date of Electronic Publication: 2024 Aug 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

المؤلفون: Detappe A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Nguyen HV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Jiang Y; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Agius MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wang W; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Mathieu C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kristufek SL; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Lundberg DJ; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Bhagchandani S; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu., Ghoroghchian PP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ppg@mit.edu.; Harvard Medical School, Boston, MA, USA. ppg@mit.edu., Johnson JA; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. jaj2109@mit.edu.

المصدر: Nature nanotechnology [Nat Nanotechnol] 2023 Sep; Vol. 18 (9), pp. 1116.

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101283273 Publication Model: Print Cited Medium: Internet ISSN: 1748-3395 (Electronic) Linking ISSN: 17483387 NLM ISO Abbreviation: Nat Nanotechnol Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Sklavenitis-Pistofidis R; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece., Lightbody ED; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Reidy M; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tsuji J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Aranha MP; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Huynh D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chong SJF; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hackett L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haradhvala NJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Wu T; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Berrios B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Alberge JB; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dutta A; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Davids MS; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Papaioannou M; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Hematology Unit, 1st Internal Medicine Department, AHEPA University Hospital, Thessaloniki, Greece., Getz G; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Ghobrial IM; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000, France.; Department of Hematology, CHU Lille, Lille University, 59000, France.

المصدر: BioRxiv : the preprint server for biology [bioRxiv] 2023 Aug 03. Date of Electronic Publication: 2023 Aug 03.

نوع المنشور: Preprint

بيانات الدورية: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

المؤلفون: Dutta AK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Alberge JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Lightbody ED; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Boehner CJ; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Dunford A; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Mouhieddine TH; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Cowan AN; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Su NK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Horowitz EM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Barr H; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Hevenor L; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Beckwith JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Perry J; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Cao A; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Lin Z; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kuhr FK; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Mastro RGD; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Nadeem O; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Greipp PT; Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota., Stewart C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Auclair D; Multiple Myeloma Research Foundation, Norwalk, Connecticut., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

المصدر: Cancer discovery [Cancer Discov] 2023 Feb 06; Vol. 13 (2), pp. 348-363.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Neoplastic Cells, Circulating*/pathology , Multiple Myeloma*/genetics , Multiple Myeloma*/pathology, Humans ; Base Sequence ; Bone Marrow ; Whole Genome Sequencing

المؤلفون: Detappe A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Nguyen HV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Jiang Y; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Window Therapeutics, Boston, MA, USA., Agius MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Wang W; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Mathieu C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kristufek SL; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Lundberg DJ; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Bhagchandani S; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Irene_Ghobrial@dfci.harvard.edu., Ghoroghchian PP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ppg@mit.edu.; Harvard Medical School, Boston, MA, USA. ppg@mit.edu., Johnson JA; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. jaj2109@mit.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. jaj2109@mit.edu.

المصدر: Nature nanotechnology [Nat Nanotechnol] 2023 Feb; Vol. 18 (2), pp. 184-192. Date of Electronic Publication: 2023 Jan 26.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101283273 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1748-3395 (Electronic) Linking ISSN: 17483387 NLM ISO Abbreviation: Nat Nanotechnol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/pathology , Prodrugs*, Humans ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology

المؤلفون: Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aranha MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Redd RA; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Baginska J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haradhvala NJ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA 02138, USA., Hallisey M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dutta AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Savell A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Varmeh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Ujwary S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Zavidij O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aguet F; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Wu T; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Flechon L; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France., Anand S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Rosenblatt JM; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Zonder J; Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA., Vredenburgh JJ; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Boruchov A; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Bhutani M; Levine Cancer Institute, Charlotte, NC 28204, USA., Usmani SZ; Levine Cancer Institute, Charlotte, NC 28204, USA., Matous J; Colorado Blood Cancer Institute, Denver, CO 80218, USA., Yee AJ; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Jakubowiak A; University of Chicago Cancer Center, Chicago, IL 60637, USA., Laubach J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France; Department of Hematology, CHU Lille, Lille University, 59000 Lille, France., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Badros AZ; University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA., Mateos MV; University Hospital of Salamanca - Instituto de Investigación Biomédica de Salamanca, 37007 Salamanca, Spain., Trippa L; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Getz G; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: gadgetz@broadinstitute.org., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.

المصدر: Cancer cell [Cancer Cell] 2022 Nov 14; Vol. 40 (11), pp. 1358-1373.e8.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Smoldering Multiple Myeloma*/therapy, Humans ; Biomarkers ; Disease Progression ; Immunologic Factors ; Immunotherapy ; Lenalidomide/adverse effects ; Clinical Trials, Phase II as Topic

المؤلفون: Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY., Redd R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Lampe L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Faculty of Medicine, Kiel University, Kiel, Germany., Nilsson KI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., El-Khoury H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Nassar AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Adib E; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Bindra G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Abou Alaiwi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard T. H. Chan School of Public Health, Boston, MA., Steensma DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Castillo JJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA; and., Treon SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA; and., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.; Broad Institute, Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA.

المصدر: Blood advances [Blood Adv] 2022 Apr 12; Vol. 6 (7), pp. 2230-2235.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation* , Waldenstrom Macroglobulinemia*/genetics , Waldenstrom Macroglobulinemia*/pathology, Clonal Hematopoiesis ; Humans ; Immunoglobulin M ; Transplantation, Autologous

المؤلفون: Shen YJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Mishima Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Shi J; State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.; Shanghai Institute of Biochemistry and Cell Biology (SIBCB), University of Chinese Academy of Sciences, Beijing, China., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Redd RA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA., Moschetta M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Manier S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Roccaro AM; ASST Spedali Civili di Brescia, Clinical Research Development and Phase I Unit, CREA Laboratory, Brescia, Italy., Sacco A; ASST Spedali Civili di Brescia, Clinical Research Development and Phase I Unit, CREA Laboratory, Brescia, Italy., Tai YT; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Mercier F; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA., Kawano Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Berrios B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Doench JG; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Root DE; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA., Michor F; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA; and., Scadden DT; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA.

المصدر: Blood [Blood] 2021 Apr 29; Vol. 137 (17), pp. 2360-2372.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Disease Models, Animal* , Gene Expression Regulation, Neoplastic*, Adaptor Proteins, Signal Transducing/*metabolism , Biomarkers, Tumor/*metabolism , HMGA1a Protein/*metabolism , Multiple Myeloma/*pathology , Neoplasm Recurrence, Local/*pathology , RNA-Binding Proteins/*metabolism, Adaptor Proteins, Signal Transducing/antagonists & inhibitors ; Adaptor Proteins, Signal Transducing/genetics ; Animals ; Apoptosis ; Biomarkers, Tumor/genetics ; Bone Marrow/metabolism ; Bone Marrow/pathology ; CRISPR-Cas Systems ; Cell Adhesion ; Cell Movement ; Cell Proliferation ; Clonal Evolution ; Disease Progression ; Female ; HMGA1a Protein/antagonists & inhibitors ; HMGA1a Protein/genetics ; Humans ; Mice ; Mice, SCID ; Multiple Myeloma/genetics ; Multiple Myeloma/metabolism ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/metabolism ; Prognosis ; RNA-Binding Proteins/antagonists & inhibitors ; RNA-Binding Proteins/genetics ; Survival Rate ; Tumor Cells, Cultured

المؤلفون: Zavidij O; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Haradhvala NJ; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital, Boston, MA, USA.; Harvard Biophysics Graduate Program, Harvard University, Boston, MA, USA., Mouhieddine TH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sklavenitis-Pistofidis R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Cai S; Harvard Medical School, Boston, MA, USA.; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, MA, USA., Reidy M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Rahmat M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Flaifel A; Harvard Medical School, Boston, MA, USA.; Specialized Histopathology Core, Brigham and Women's Hospital, Boston, MA, USA., Ferland B; Specialized Histopathology Core, Brigham and Women's Hospital, Boston, MA, USA., Su NK; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Agius MP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Park J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Manier S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Bustoros M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Huynh D; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Capelletti M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Berrios B; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu CJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., He MX; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard Biophysics Graduate Program, Harvard University, Boston, MA, USA., Braggio E; Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA., Fonseca R; Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA., Maruvka YE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Guerriero JL; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Goldman M; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Van Allen EM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., McCarroll SA; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Azzi J; Harvard Medical School, Boston, MA, USA.; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, MA, USA., Getz G; Harvard Medical School, Boston, MA, USA. gadgetz@broadinstitute.org.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. gadgetz@broadinstitute.org.; Massachusetts General Hospital, Boston, MA, USA. gadgetz@broadinstitute.org., Ghobrial IM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. irene_ghobrial@dfci.harvard.edu.

المصدر: Nature cancer [Nat Cancer] 2020 May; Vol. 1 (5), pp. 493-506. Date of Electronic Publication: 2020 Apr 27.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer

مواضيع طبية MeSH: Monoclonal Gammopathy of Undetermined Significance*/genetics , Multiple Myeloma*/genetics , Smoldering Multiple Myeloma*, Animals ; Humans ; Mice ; Sequence Analysis, RNA ; Tumor Microenvironment/genetics